- Home
- » Tags
- » Inovio Pharmaceuticals
Top View
- INOVIO Reports First Quarter 2021 Financial Results
- GUIDE to the CORONAVIRUS DRUG PIPELINE CORONAVIRUS OUTBREAK: New Vaccines in the Pipelines of Leading Pharmaceutical Companies
- Case 2:20-Cv-01402-GJP Document 80 Filed 12/21/20 Page 1 of 35
- COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System As a Potential Vaccine Platform
- Inovio Pharmaceuticals, Inc. (Exact Name of Registrant As Specified in Its Charter)
- Inovio Pharmaceuticals, Inc. (Exact Name of Registrant As Specified in Its Charter)
- Dear Investor, Thank You for Requesting Information About Inovio
- Inovio Pharmaceuticals, Inc
- Pandemic Profiteering
- Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus
- Safety and Immunogenicity of INO-4800 DNA Vaccine Against SARS-Cov-2
- Multivalent DNA Vaccines As a Strategy to Combat Multiple Concurrent Epidemics: Mosquito-Borne and Hemorrhagic Fever Viruses
- Case 2:20-Cv-01402-GJP Document 68 Filed 09/21/20 Page 1 of 68
- INOVIO Planning for Ex-US Global Phase 3 Trial for INO-4800
- Inovio Pharmaceuticals Annual Report 2021
- DRAFT Landscape of COVID-19 Candidate Vaccines – 15 October 2020
- Inovio Pharmaceuticals, Inc
- INOVIO and Advaccine Announce Exclusive Partnership to Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China
- 2017 Vaccines in Development
- INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses in Non- Human Primates Challenged with SARS-Cov-2 Virus
- Inovio Pharmaceuticals, Inc. (Exact Name of Registrant As Specified in Its Charter)
- INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 with New Funding from CEPI
- Inovio Pharmaceuticals, Inc
- INOVIO PHARMACEUTICALS, INC., and J
- Preclinical Evaluation of Multi Antigenic HCV DNA Vaccine for the Prevention of Hepatitis C Virus Infection
- INOVIO Receives Authorization to Conduct Phase 3 E Cacy Trial of Its
- Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
- INOVIO Initiates Phase 1 Clinical Trial of Its COVID-19 Vaccine and Plans First Dose Today
- VGX-3100) for Precancerous Through Proprietary Smart Device Cervical Dysplasia
- Clinical Research Protocol
- Inovio Receives NIH Funding to Target Its Dmab® Technology Against Antimicrobial-Resistant Infection